Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.65 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31047345 | 0.91 | POLB (0.53) | PARP1PARP2POLBMAPTMEN1 | |
| SCHEMBL3790798 | 0.84 | PARP1 (0.47) | PARP1PARP2POLBMAPTMEN1 | |
| SCHEMBL7215446 | 0.82 | PARP1 (0.61) | PARP1PARP2POLBMAPTGAA | |
| SCHEMBL5619945 | 0.79 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL7956612 | 0.78 | PARP1 (0.57) | PARP1PARP2POLBMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL18614383 | 0.78 | PARP1 (0.97) | PARP1PARP2 | |
| SCHEMBL5620711 | 0.77 | PARP1 (0.79) | PARP1PARP2 | |
| SCHEMBL6872238 | 0.76 | PARP1 (0.68) | PARP1PARP2 | |
| SCHEMBL5620662 | 0.76 | PARP1 (0.76) | PARP1PARP2 | |
| SCHEMBL6872911 | 0.76 | PARP1 (0.61) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188011-B1 | Optimization of ligand affinity for RNA targets using mass spectrometry | ISIS PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2005023986-A2 | MICRORNA AS LIGANDS AND TARGET MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1183091-A4 | OPTIMIZATION OF LIGAND AFFINITY FOR RNA TARGETS USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6770486-B1 | IDENTIFICATION OF LIGAND COMPOUNDS THAT BIND TO TARGET MOLECULES SUCH AS PROTEINS OR STRUCTURED RNA WITH AS LITTLE AS MILLIMOLAR (MM) AFFINITY USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1183091-A1 | OPTIMIZATION OF LIGAND AFFINITY FOR RNA TARGETS USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001058573-A1 | OPTIMIZATION OF LIGAND AFFINITY FOR RNA TARGETS USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |